PMID- 21813733
OWN - NLM
STAT- MEDLINE
DCOM- 20111207
LR  - 20151119
IS  - 1945-1997 (Electronic)
IS  - 0098-6151 (Linking)
VI  - 111
IP  - 7 Suppl 5
DP  - 2011 Jul
TI  - Novel incretin-based agents and practical regimens to meet needs and treatment 
      goals of patients with type 2 diabetes mellitus.
PG  - S20-30
AB  - As knowledge of pathophysiologic mechanisms of diabetes mellitus has increased, 
      clinical attention has shifted to the incretin system. Incretin hormones, 
      including glucagon-like peptide-1, or GLP-1, and glucose-dependent insulinotropic 
      polypeptide, are vital to the control of glucose homeostasis and pancreatic 
      beta-cell preservation. Novel strategies for the treatment of patients with type 2 
      diabetes mellitus (T2DM) engage the incretin system. Glucagon-like peptide-1 
      receptor agonists provide robust glycemic control as well as beneficial 
      reductions in body weight. Dipeptidyl peptidase-4, or DPP-4, inhibitors exhibit 
      beneficial glycemic effects and are weight-neutral. Incretin-based medications 
      are becoming increasingly recognized in guidelines as early treatment options 
      because of their efficacy and well-tolerated profiles. The author reviews the 
      safety and efficacy of currently approved incretin-based agents, as well as the 
      role of these medications in treatment paradigms for patients with T2DM. He also 
      discusses investigational incretin-based agents.
FAU - Garber, Alan J
AU  - Garber AJ
AD  - Department ofMedicine, Biochemistry, and Molecular Biology, Baylor College of 
      Medicine, 1 Baylor Plaza, Houston, TX 77030-3411, USA. agarber@bcm.edu
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Am Osteopath Assoc
JT  - The Journal of the American Osteopathic Association
JID - 7503065
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Incretins)
RN  - 0 (Purines)
RN  - 0 (Quinazolines)
RN  - 3X29ZEJ4R2 (Linagliptin)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
EIN - J Am Osteopath Assoc. 2011 Nov;111(11):604
MH  - Adult
MH  - Aged
MH  - Blood Glucose/drug effects/metabolism
MH  - Diabetes Mellitus, Type 2/diagnosis/*drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/*administration & dosage
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Female
MH  - Follow-Up Studies
MH  - Glucagon-Like Peptide 1/administration & dosage/*analogs & derivatives
MH  - Humans
MH  - Incretins/*administration & dosage/metabolism
MH  - Linagliptin
MH  - Male
MH  - Middle Aged
MH  - Purines
MH  - Quinazolines
MH  - Randomized Controlled Trials as Topic
MH  - Severity of Illness Index
MH  - Treatment Outcome
EDAT- 2011/08/10 06:00
MHDA- 2011/12/13 00:00
CRDT- 2011/08/05 06:00
PHST- 2011/08/05 06:00 [entrez]
PHST- 2011/08/10 06:00 [pubmed]
PHST- 2011/12/13 00:00 [medline]
AID - 111/7_suppl_5/S20 [pii]
PST - ppublish
SO  - J Am Osteopath Assoc. 2011 Jul;111(7 Suppl 5):S20-30.